Can immune markers predict breast cancer treatment success?

NCT ID NCT07570524

Recruiting now Knowledge-focused Sponsor: Center Eugene Marquis Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study looks at 200 women with early-stage triple-negative breast cancer to find immune markers in tumors and blood that predict whether immunochemotherapy will work well. Researchers will compare those who have a complete response to those who don't, aiming to guide more personalized treatment in the future. Participants give extra biopsies and blood samples over 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors personalize treatment for triple-negative breast cancer by identifying who will benefit most from immunochemotherapy.
What could go wrong: This is an observational study that does not test a new treatment. It may not find clear biomarkers, and results may not change practice for years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER (TNBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Locations

Centre Eugène Marquis
RECRUITING

Rennes, 35000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.